Dr. Ole-Petter Riksfjord Hamnvik, MD

Dr. Hamnvik practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Hamnvik's NPI, 1063603678, was assigned on August 8, 2007. Dr. Hamnvik graduated from Royal College of Surgeons Ireland in 2005. Dr. Hamnvik holds Massachusetts license 239696.

Dr. Hamnvik's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Hamnvik's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Hamnvik is also affiliated with Massachusetts General Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Dr. Hamnvik to 3 more hospitals, 1 hospital outpatient department and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hamnvik practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hamnvik's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Hamnvik is board certified in endocrinology, diabetes and metabolism by the American Board of Internal Medicine. Dmand AI has Dr. Hamnvik's licenses on file in 5 states: Massachusetts, Maine, New Hampshire, Rhode Island and Connecticut.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, hypercalcemia, osteoporosis, overactive thyroid, parathyroid gland disorder and testicular dysfunction among the conditions Dr. Hamnvik treats.

CMS data shows 285 Medicare services from Dr. Hamnvik across 4 procedure codes in 2024, for 168 Medicare patients. Medicare paid $14,665 for them.

CMS counts 168 Medicare patients who saw Dr. Hamnvik in 2024. The largest group is 65 to 74, with 74 patients. 70% of them have high cholesterol, and 68% have high blood pressure. 24% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hamnvik's median patient age at 66, with 63% women.

In 2024, Dr. Hamnvik wrote 687 Medicare Part D claims for 105 patients. 60% of them were for generic drugs. CMS names the drug for 509 of them, across 16 drugs with 11 or more claims each, at $185,911 in total drug cost. In 2023, CMS named 734 claims across 24 drugs.

Dr. Hamnvik accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hamnvik as offering telehealth.

Dmand AI links 51 papers to Dr. Hamnvik, published from 2008 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Transgender Persons, Bone Density and Diabetes Mellitus, Type 2. Dr. Hamnvik has published most often in N Engl J Med. Dr. Hamnvik's most frequent co-authors are Yee-Ming Melody Cheung, MD, PhD, Toni K. Choueiri, MD and Rana Ramzi McKay, MD.

CMS Open Payments shows 3 general payments to Dr. Hamnvik from 2 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 91% of the total. Merck Sharp & Dohme Corporation paid the most, $500.

Dmand AI lists 25 awards for Dr. Hamnvik, most recently Fellowship Teaching Award, Endocrinology in 2013.

Dr. Hamnvik graduated from Royal College of Surgeons Ireland in 2005. Dr. Hamnvik is a member of AACE and ENDO.

Dr. Hamnvik is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.